Research analysts at Cantor Fitzgerald boosted their target price on shares of Salix Pharmaceuticals (NASDAQ: SLXP) from $60.00 to $63.00 in a report released on Monday. The firm currently has a “buy” rating on the stock.
Salix Pharmaceuticals traded down 1.19% on Monday, hitting $48.84. Salix Pharmaceuticals has a 52-week low of $37.52 and a 52-week high of $55.99. The stock’s 50-day moving average is currently $48.39. The company has a market cap of $2.987 billion and a price-to-earnings ratio of 48.94.
Salix Pharmaceuticals last released its earnings data on Thursday, February 28th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.03. The company had revenue of $198.17 million for the quarter, compared to the consensus estimate of $199.41 million. During the same quarter last year, the company posted $1.18 earnings per share. Salix Pharmaceuticals’s revenue was up 27.7% compared to the same quarter last year. Salix Pharmaceuticals has set its FY13 guidance at approx $3.37 EPS. On average, analysts predict that Salix Pharmaceuticals will post $3.39 earnings per share for the current fiscal year.
A number of other firms have also recently commented on SLXP. Analysts at Brean Murray raised their price target on shares of Salix Pharmaceuticals from $44.00 to $53.00 in a research note to investors on Friday, March 1st. They now have a “buy” rating on the stock. Separately, analysts at Janney Montgomery Scott initiated coverage on shares of Salix Pharmaceuticals in a research note to investors on Thursday, January 31st. They set a “buy” rating and a $55.00 price target on the stock. Finally, analysts at RBC Capital initiated coverage on shares of Salix Pharmaceuticals in a research note to investors on Friday, January 11th. They set an “outperform” rating and a $53.00 price target on the stock.
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal diseases, which are those affecting the digestive tract.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
